Buy tech sell-off, Wedbush’s Ives says: ’this is a 1996 moment, not 1999’
DUBLIN - Investment firm Citadel Group has disclosed a 1.34% stake in Mural Oncology plc, according to a regulatory filing published Tuesday.
The filing, made under Irish Takeover Panel rules, shows Citadel holds 232,915 shares representing interests in the biopharmaceutical company, while also maintaining short positions equivalent to 1.11% of Mural’s outstanding shares.
The disclosure details that Citadel owns or controls 219,515 common shares directly, representing 1.26% of the company. The remaining portion of its long position consists of stock-settled derivatives including options amounting to 0.07% of Mural’s shares.
Citadel’s short position of 1.11% is entirely comprised of stock-settled derivatives, according to the filing.
The investment firm also reported several transactions conducted on October 6, including purchases of 2,600 shares at prices ranging from $2.08 to $2.09 per share, and sales of 313 shares at similar price points.
The disclosure includes details of Citadel’s options positions, with various put and call options expiring between October 2025 and January 2027, with strike prices ranging from $2.50 to $7.50.
Irish Takeover Panel rules require investors holding interests of 1% or more in companies potentially involved in takeover situations to disclose their positions.
Mural Oncology, listed on the Irish stock exchange with shares priced around $2.08 based on the reported transactions, focuses on cancer therapeutics development.
This information was disclosed through a regulatory filing submitted to the Irish Takeover Panel.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.